The William B. Abrams Lecture is a joint educational initiative of ASCPT and the FDA. The lecture series, supported in part by The Merck Company Foundation, was established in 1999 to honor William B. Abrams, MD, an ASCPT president from 1975 to 1976.
Among his many accomplishments, Dr. Abrams worked at the FDA as the first special government employee to establish the Center for Drug Evaluation and Research Staff College and develop its curriculum. He also had a distinguished career in the pharmaceutical industry as a longtime employee of Merck Research Laboratories.
For more than 10 years, ASCPT and the FDA have invited experts from academia, industry, and government to discuss advances in clinical pharmacology and drug development. These scientists have excelled in their specialty areas and are some of the most highly esteemed clinical pharmacologists in the field. Their presentations convey novel information and perspectives on fundamental aspects of clinical pharmacology. Previous lectures have included speakers from the Mayo Clinic, University of California, Children's Mercy Hospitals and Clinics, and the National Institutes of Health.
2022 ASCPT & FDA William B. Abrams Lecture
The 2022 ASCPT & FDA William Abrams Lecture Award recipient is Lawrence Lesko, PhD, Clinical Professor Emeritus at the University of Florida.
: Therapeutic Individualization: What Is It Exactly?
: May 4, 2022
Dr. Lesko will present a perspective on the many faces of therapeutic individualization and define it in the context of 3 things: the clinical question, the technology needed, and the clinical decision. He will give examples of authentic individualization and subgroup individualization based on subgroup attributes. Dr. Lesko will present some innovative computational and model-based approaches to therapeutic individualization that addresses drug safety questions and delves into the molecular pathways and signaling pathways of clinical adverse events to better understand them and mitigate risk. Finally, he will present a unique example of how Bayesian-based precision dosing can optimize gene therapy.
- Be able to discuss the scope and meaning of therapeutic individualization
- Differentiate between individualization strategies for a single patient vs subgroup individualization based on intrinsic and/or extrinsic factors, and
- Recognize how technology such as therapeutic drug monitoring coupled with Bayesian statistics and systems pharmacology models can enable therapeutic individualization in areas of efficacy and safety.
This activity is intended for physicians, pharmacists, nurses, FDA scientific community, and other health professionals who review medical products, perform regulatory science research, and set regulatory science policy.
If you have any questions about the ASCPT & FDA Abrams Award please contact Elise Laffman-Johnson